Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

The pharmacological advantages of the rapid-acting analog, insulin aspart, over human insulin have contributed to the widespread prescription of the premix, biphasic insulin aspart 30/70 (BIAsp 30), in type 1 (T1DM) and type 2 diabetes (T2DM). This article reviews the available literature on the pha...

Descripción completa

Detalles Bibliográficos
Autor principal: Valensi, Paul
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048020/
https://www.ncbi.nlm.nih.gov/pubmed/21437119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048020/
https://www.ncbi.nlm.nih.gov/pubmed/21437119

Ejemplares similares